Athersys (NASDAQ:ATHX) has obtained a U.S. patent that covers the use of nonembryonic multi-potent stem cells for the treatment of several heart conditions, including heart attack. The patent provides protection for “multiple techniques” for delivering the stem cells to treat the conditions, which also include congestive heart failure and myocardial ischemia, according to a statement […]
A new common stock purchase agreement with Aspire Capital Fund LLC will give Cleveland biopharmaceutical company Athersys (NASDAQ:ATHX) up to $20 million in investment dollars. Chicago-based Aspire has committed to purchasing up to $20 million in Athersys common stock over the next two years, with Athersys controlling the timing and the amount of the purchases […]
Athersys (Nasdaq:ATHX) has entered a partnership with a nonprofit multiple sclerosis group to investigate its adult stem cell technology for the treatment of MS. Fast Forward, a nonprofit subsidiary of the National Multiple Sclerosis Society, will commit up to $640,000 to fund animal studies of Athersys’ MultiStem in treating MS, a disease that attacks the […]
Stem cell developer Athersys (NASDAQ:ATHX) has taken the next of many steps toward commercializing its MultiStem therapy for stroke, the most promising application for the therapy. The Cleveland-based company detailed its plans for a phase 2 ischemic stroke clinical trial that’s estimated to involve about 140 patients, according to ClinicalTrials.gov, a website maintained by the […]
Stem cell therapy developer Athersys (NASDAQ:ATHX) plans to begin phase 2 clinical trials of its MultiStem therapy for stroke and heart attack patients by the end of the year. Moving ahead with its stroke therapy is key for Athersys because that application represents its biggest market. CEO Gil Van Bokkelen pegged the potential stroke market […]
As a small biotech with little revenue, no profits and no products on the market, stem cell therapy developer Athersys (NASDAQ:ATHX) is particularly vulnerable to big drops in its share price. That’s because Athersys’s primary method for raising cash is through direct offerings of its shares, such as an offering that raised $13 million for […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Athersys (NASDAQ:ATHX) reported that results from a phase 1 trial of its stem cell therapy suggest its MultiStem technology could hold benefits for heart attack patients. The positive results from a one-year followup on the trial will pave the way for Cleveland-based Athersys to begin a phase 2 trial on heart attack patients later this […]
Stem cell therapy developer Athersys (NASDAQ:ATHX) reported positive interim results from a phase 1 clinical trial in patients with leukemia or similar blood cancers. The trial showed that the company’s MultiStem technology was well tolerated at all dose levels and also suggested that the technology may reduce the incidence of severe graft-versus-host disease, according to […]
Stem cell therapy developer Athersys (NASDAQ:ATHX) plans to begin the first clinical study of its MultiStem technology in stroke patients by the end of the year. The planned double-blind, placebo-controlled study could involve as many as 150 patients, CEO Gil Van Bokkelen said in a conference call with analysts and investors after announcing the Cleveland-based […]
Stem cell therapy developer Athersys (NASDAQ:ATHX) and partner Pfizer (NYSE:PFE) have begun enrolling patients in a phase 2 clinical trial for inflammatory bowel disease.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Stem cell company Athersys Inc. (NASDAQ:ATHX) has reached an agreement to sell about $13 million of its shares to unidentified private investors.
Stem cell company Athersys completed a study showing its technology could hold therapeutic benefits in treating spinal cord injuries. Researchers found that administering Athersys' MultiStem technology to rodents with spinal injuries reduced inflammation and promoted the regrowth of neurons.
Athersys Inc. (NASDAQ:ATHX) has completed patient enrollment in the single-dose portion of a clinical trial that's treating blood cancer patients with the company's stem cell therapy.
Floyd Loop, the former Cleveland Clinic CEO credited with turning around the once-struggling hospital, has resigned from the board of stem cell company Athersys Inc. (NASDAQ:ATHX).
A former custodian with stem cell developer Athersys (NASDAQ:ATHX) has been accused by federal prosecutors of running a stock scam that bilked would-be investors out of $340,000 over six years.
